MRI magnetic resonance scanner. Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Imricor Medical Systems’ (ASX:IMR) shares were up 2.17% in lunchtime trades on news the company is one step closer to launching a medical trial in Switzerland to test its MRI-machine-compatible ‘VISABL-AFL’ heart devices.

Imricor’s relationship with the Swiss Lausanne University Hospital (LUH) has further advanced as the company wins approval from its ethics committee to conduct such a trial.

LUH requires one more approval to participate in the trial; Swiss entity Swissmedic needs to give the final greenlight.

Should that occur, LUH will become the second university hospital alongside John Hopkins to join an Imricor trial.

The entity is confident it can win approval from Swissmedic – such that LUH already has a built-out facility on-site to cater specifically to Imricor’s products.

After LUH and John Hopkins, Imricor is hoping to angle into Amsterdam and South Paris.

“Our clinical team’s plans for executing an efficient multi-centre study for VISABL-AFL is on track, which means our FDA process and US launch are also on track,” Imricor chief Steve Wedan said.

That US launch is the ultimate prize for Imricor – which needs FDA approval to kick off.

The ultimate value proposition Imricor puts forward is that it can advance the utility of an MRI machine where cardiac concerns are involved by having safe-to-use devices active in the body while the scan takes place.

MRI machines ultimately rely on extremely strong magnetic fields to image the human body and are notorious for being dangerous to operate when metallic objects are in the room.

MRIs are perhaps the most advanced machine humanity has ever commercialised on a mass scale.

Imricor (ASX:IMR) shares were up 2.17% to 47cps in lunchtime trades.

IMR by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Bourse finishes week on a high as Wisetech pummeled | November 22, 2024

The ASX200 closed up 0.85% at 8,393 points. Economists increasingly expect interest rates in Australia won’t…
The Market Online Video

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing,…
Nuclear explosion mushroom cloud concept

Week 47 Wrap: HotCopper users’ most watched; Brent lifts on Putin’s scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching…
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Dale Gillham’s weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in th…